PMID- 31387095
OWN - NLM
STAT- MEDLINE
DCOM- 20210128
LR  - 20210128
IS  - 1423-0267 (Electronic)
IS  - 0030-3755 (Print)
IS  - 0030-3755 (Linking)
VI  - 243
IP  - 2
DP  - 2020
TI  - Outcome Predictors of SD-OCT-Driven Intravitreal Ranibizumab in Choroidal 
      Neovascularization due to Myopia.
PG  - 154-162
LID - 10.1159/000501040 [doi]
AB  - PURPOSE: To analyze the efficacy and outcome predictors of SD-OCT 
      (spectral-domain optical coherence tomography)-driven ranibizumab treatment in 
      patients with choroidal neovascularization due to myopia (mCNV). METHODS: This 
      prospective investigator-initiated study includes 20 patients with 
      treatment-naive mCNV. Evaluation included best-corrected visual acuity (BCVA), 
      morphological SD-OCT parameters, and treatment frequency. RESULTS: From baseline 
      to month 12, BCVA improved from 58.5 +/- 16.9 to 66.1 +/- 14.9 letters. Central 
      retinal thickness (CRT) significantly decreased, and qualitative SD-OCT 
      parameters improved. Better baseline visual acuity (VA), lower spherical 
      equivalent, better inner/outer segment line and external limiting membrane 
      integrity showed a significant positive effect on BCVA outcome. Less fluctuation 
      in CRT (worst minus best CRT) indicated better BCVA at 12 months. No serious 
      adverse events occurred. CONCLUSIONS: SD-OCT-guided intravitreal ranibizumab 
      treatment in mCNV was efficient and safe. We determined useful predictive factors 
      in regard to VA outcome after 12 months.
CI  - The Author(s). Published by S. Karger AG, Basel.
FAU - Guichard, Maria-Magdalena
AU  - Guichard MM
AD  - Vista Klinik, Binningen, Switzerland.
FAU - Peters, Geraldine
AU  - Peters G
AD  - Vista Klinik, Binningen, Switzerland.
FAU - Tuerksever, Cengiz
AU  - Tuerksever C
AD  - Vista Klinik, Binningen, Switzerland.
FAU - Pruente, Christian
AU  - Pruente C
AD  - Department of Ophthalmology, University of Basel, Basel, Switzerland.
AD  - Department of Ophthalmology, Kantonsspital Liestal, Liestal, Switzerland.
FAU - Hatz, Katja
AU  - Hatz K
AD  - Vista Klinik, Binningen, Switzerland, katja.hatz@vista.ch.
AD  - Department of Ophthalmology, University of Basel, Basel, Switzerland, 
      katja.hatz@vista.ch.
LA  - eng
PT  - Journal Article
DEP - 20190806
PL  - Switzerland
TA  - Ophthalmologica
JT  - Ophthalmologica. Journal international d'ophtalmologie. International journal of 
      ophthalmology. Zeitschrift fur Augenheilkunde
JID - 0054655
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - Aged
MH  - Angiogenesis Inhibitors/administration & dosage
MH  - Choroidal Neovascularization/drug therapy
MH  - Female
MH  - Fluorescein Angiography/methods
MH  - Follow-Up Studies
MH  - Fundus Oculi
MH  - Humans
MH  - Intravitreal Injections
MH  - Male
MH  - Myopia, Degenerative/*complications/diagnosis
MH  - Prognosis
MH  - Prospective Studies
MH  - Ranibizumab/*administration & dosage
MH  - Tomography, Optical Coherence/*methods
MH  - Vascular Endothelial Growth Factor A/antagonists & inhibitors
MH  - *Visual Acuity
PMC - PMC7114905
OTO - NOTNLM
OT  - Choroidal neovascularization
OT  - Myopia
OT  - Predictor
OT  - Ranibizumab
OT  - SD-OCT
COIS- This study was supported in part by Novartis Switzerland; further Novartis 
      Switzerland also provided open access funding but had no influence on the study 
      or the content of the manuscript. Prof. Pruente and Dr. Hatz independently 
      received financial compensation from Novartis Switzerland, Bayer Switzerland, 
      Alcon, Allergan, and Roche for consultancies and contract research. None of the 
      authors reports other financial interests in terms of the presented study.
EDAT- 2019/08/07 06:00
MHDA- 2021/01/29 06:00
PMCR- 2019/08/06
CRDT- 2019/08/07 06:00
PHST- 2018/10/23 00:00 [received]
PHST- 2019/05/20 00:00 [accepted]
PHST- 2019/08/07 06:00 [pubmed]
PHST- 2021/01/29 06:00 [medline]
PHST- 2019/08/07 06:00 [entrez]
PHST- 2019/08/06 00:00 [pmc-release]
AID - 000501040 [pii]
AID - oph-0243-0154 [pii]
AID - 10.1159/000501040 [doi]
PST - ppublish
SO  - Ophthalmologica. 2020;243(2):154-162. doi: 10.1159/000501040. Epub 2019 Aug 6.